Article Text

PDF
Original article
A retrospective chart review of the features of PTEN hamartoma tumour syndrome in children
  1. Emily Hansen-Kiss1,
  2. Sarah Beinkampen2,
  3. Brent Adler3,
  4. Thomas Frazier4,
  5. Thomas Prior5,
  6. Steven Erdman6,7,
  7. Charis Eng8,9,
  8. Gail Herman2,6
  1. 1Center for Molecular and Human Genetics, Nationwide Children's Hospital, Westerville, Ohio, USA
  2. 2Center for Molecular and Human Genetics, The Research Institute at Nationwide Children's Hospital, Columbus, Ohio, USA
  3. 3Department of Radiology, The Ohio State University, Columbus, Ohio, USA
  4. 4Center for Autism, Cleveland Clinic Children's, Cleveland, Ohio, USA
  5. 5Department of Medical Genetics, Ohio State University, Columbus, USA
  6. 6Department of Pediatrics, The Ohio State University, Columbus, Ohio, USA
  7. 7Gastroenterology, Hepatology, and Nutrition, Nationwide Children's Hospital, Columbus, Ohio, USA
  8. 8Cleveland Clinic Genomic Medicine Institute, Ohio, USA
  9. 9Genetics and Genomics Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA
  1. Correspondence to Emily Hansen-Kiss, Molecular and Human Genetics, Nationwide Children's Hospital, 187 West Schrock Rd, Westerville, OH 43081, USA; emily.hansen-kiss{at}nationwidechildrens.org

Abstract

Objective It is recognised that 5% – 10 % of children with macrocephaly and autism spectrum disorder (ASD) and/or intellectual disability (ID) have a heterozygous pathogenic mutation in the PTEN tumour suppressor gene that is associated with PTEN hamartoma tumour syndrome. However, the clinical features and course in children with a pathogenic PTEN mutation are unclear and have not been well documented.

Study objectives We undertook a retrospective chart review of children (< 18  years) with pathogenic PTEN mutations to ascertain clinical findings, clinical course and possible outcomes.

Results Clinical and molecular data were collected and analysed for 47 patients with PTEN mutation from 38 eligible families. Macrocephaly (average head circumference of + 5.7  SD) with developmental delay, ID and/or ASD were the most common presenting signs/symptoms (66 %). Clinical features included dermatological findings (66 %), gastrointestinal (GI) symptoms (34 %), ASD diagnosis (50 %), abnormal brain imaging (53 % of those examined) and abnormal thyroid imaging (26 %).

Conclusions This is the largest survey of clinical features in children with PTEN pathogenic mutations to date. It confirms earlier reports of increased rates of neurodevelopmental disorders. Dermatological, GI and thyroid abnormalities are age dependent and may not be present at the time of diagnosis, requiring regular monitoring and medical surveillance. Early paediatric diagnosis is important for institution of medical and developmental surveillance as well as for testing other at- risk family members.

Statistics from Altmetric.com

Footnotes

  • Contributors All authors have seen and approved the submission of this manuscript, and take full responsibility for the manuscript. All authors critically revised the manuscript and gave final approval.

  • Competing interests EHK, TP, SB, SE, BA, CE and GH declare relevant no conflicts of interest. TF has received federal funding or research support from, acted as a consultant to, received travel support from and/or received a speaker’s honorarium from the Cole Family Research Fund, Simons Foundation, Ingalls Foundation, Forest Laboratories, Ecoeos, IntegraGen, Kugona LLC, Shire Development, Bristol-Myers Squibb, National Institutes of Health and the Brain and Behavior Research Foundation.

  • Ethics approval Nationwide Children's Hospital IRB.

  • Provenance and peer review Not commissioned; externally peer reviewed.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.